iclaprim

Known as: 5-[(2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl]-2,4-Pyrimidinediamine, 5-[(2RS)-2-Cyclopropyl-7,8-dimethoxy-2H-chromen-5-ylmethyl]pyrimidine-2,4-diamine 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2003-2018
0102020032018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
The in vitro activity of iclaprim, a novel diaminopyrimidine derivative, was evaluated against 5,937 recent gram-positive… (More)
Is this relevant?
2009
2009
OBJECTIVES Iclaprim is a novel 2,4-diaminopyrimidine that exhibits potent, rapid bactericidal activity against major Gram… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2009
2009
This study evaluated the effect of human plasma on the in vitro bactericidal activity of the novel diaminopyrimidine iclaprim… (More)
  • table 1
  • table 2
Is this relevant?
2009
2009
Iclaprim is a novel antibacterial agent that is currently in development for the treatment of complicated skin and skin structure… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2008
2008
Arpida Ltd, under license from Roche AG, is developing the diaminopyrimidine dihydrofolate reductase inhibitor iclaprim for the… (More)
Is this relevant?
2007
2007
OBJECTIVES A validated microbiological assay was used to measure concentrations of iclaprim (AR-100) in plasma, bronchial mucosa… (More)
Is this relevant?
2007
2007
OBJECTIVES Iclaprim is a novel diaminopyrimidine for which a human plasma binding level of approximately 93% has been reported… (More)
  • table 1
Is this relevant?
2007
2007
OBJECTIVES To assess the synergistic potential of the novel diaminopyrimidine iclaprim (formerly AR-100, Ro 48-2622), a specific… (More)
Is this relevant?
2004
2004
The in vitro activities of iclaprim, a novel dihydrofolate reductase inhibitor, azithromycin, and levofloxacin were tested… (More)
  • table 1
  • table 2
Is this relevant?
2003
2003
Iclaprim, a new selective dihydrofolate inhibitor was synthesized based on rational drug design. Iclaprim's interaction with a… (More)
Is this relevant?